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Modified vaccinia virus Ankara (MVA) is a highly attenuated virus strain that may be useful as a vaccine vector.
Ultrastructural examination of purified MVA showed that most of the viral particles are enveloped in contrast to the
Copenhagen strain (COP). In CsCl gradients, the majority of the MVA particles displayed a light buoyant density characteristic
of the enveloped form. Consistent with these results, MVA particles were poorly labeled with antibodies against the surface
of intracellular mature virus but strongly labeled with antibodies against an envelope antigen. Furthermore, MVA was more
resistant than the COP strain to neutralization by mouse anti-COP antibodies. These results suggest that the MVA strain may
be particularly suitable for the engineering of envelope proteins and that MVA may be able to resist the humoral immunity
displayed by previously vaccinated individuals. © 2000 Academic PressIntroduction. Modified vaccinia virus Ankara (MVA) is a
highly attenuated strain of vaccinia virus (VV) obtained by
passaging a VV isolate from Ankara, Turkey, more than
500 times in chick embryo fibroblasts (1). The host range
of MVA is considerably restricted compared to other VV
strains since it fails to multiply efficiently in most mam-
malian cells with the exception of hamster BHK 21 cells
(1–3). The host range defects have been mapped and
found to be the consequence of deletions in several
regions of the viral genome (4). Determination of the
complete sequence of the MVA genome and its compar-
ison to that of the VV Copenhagen strain (COP) has
allowed the precise identification of seven deletions and
numerous mutations leading to fragmented ORFs (5).
ecause of its high degree of attenuation, MVA has
ppeared as an attractive alternative to standard VV
trains for the development of viral vectors to be used in
accination or immunotherapy. One strategy designed to
ake full advantage of the viral life cycle in the construc-
ion of recombinant VV relies on the finding that intracel-
ular mature virus (IMV) may be enveloped in a series of
teps to give rise to extracellular enveloped virus (EEV).
n a first step, IMVs acquire a double-layer envelope by
rapping with VV modified Golgi vesicles. The outer
nvelope of these particles, designated intracellular en-
eloped virus (IEV), is lost through fusion with the cell
embrane resulting in the release at the cell surface of
ell-associated enveloped virus (CEV). In a final step, the1 To whom reprint requests should be addressed.
9CEV may detach from the cell to become truly EEV. The
envelopes of both the CEV and EEV contain virus-en-
coded membrane proteins whose genes can be fused
with foreign sequences in such a way that the proteins
they encode are displayed on the virus surface (6). This
feature has been exploited to generate recombinant
EEVs to immunize against foreign antigens (7) or as a
means of targeting VV to specific cell types (8). As a
prerequisite to employing such a strategy with MVA and
since little knowledge is currently available concerning
the ability of MVA to give rise to enveloped virions, we
have examined the formation of enveloped virus upon
MVA infection.
Results. Purified MVA particles are surrounded by an
envelope. MVA and the COP strain of VV were purified
from combined infected CEF lysates and culture medium
using an identical sucrose gradient procedure. The pu-
rified stocks were then observed under an electron mi-
croscope after negative staining. MVA particles were
often clumped together (Fig. 1C) in contrast to Cop par-
ticles (Fig. 1A). Furthermore, MVA particles displayed a
smooth surface (Fig. 1D) unlike the COP particles (Fig.
1B), which usually had a rough appearance referred to
as the mulberry form. The majority of the MVA particles
also displayed a surrounding envelope (Fig. 1D) that was
not apparent in particles of the COP strain (Fig. 1B). The
rough surface of purified VV particles has been consid-
ered evidence for the presence of tubules on the IMV
surface. However, cryoelectron microscopic observa-
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appear during the staining and dehydration procedures
required for observation by standard EM methods (9).
The presence of an additional envelope surrounding
MVA particles could prevent the occurrence and/or visu-
alization of such artifacts. Further evidence for an extra
envelope surrounding MVA particles was provided by
examination of unstained virus using cryoelectron mi-
croscopy (results not shown).
Enveloped virus predominates in intracellular and ex-
tracellular fractions of MVA-infected cells. The additional
envelope surrounding MVA particles could appear
through the process known to give rise to IEV, CEV, and
EEV. To investigate the relative production of extracellu-
lar virus released into the medium as well as cell asso-
ciated virus, we titrated both fractions produced after
infection of chick embryo fibroblasts. Over a 2-day pe-
riod, the MVA and COP strains produced a similar
amount of cell-associated virus; however, MVA produced
a 20- to 40-fold larger amount of extracellular virus than
the COP strain (not shown). In agreement with this result
the EEV protein B5R was detected in much larger
FIG. 1. Electron microscopy of negatively stained MVA and COP. C
staining. A and B: Two different enlargements of COP particles; C and D
in the bottom right-hand corner of each panel.amounts in the extracellular fractions of MVA-infected
cells than in similar fractions from COP-infected cells(not shown). To quantify the ratio of enveloped virus
versus unenveloped virus in the medium and cell lysates
we submitted the two fractions to density gradient anal-
ysis (Fig. 2). The COP particles produced were essen-
tially cell associated (78%) and sedimented at 1.28 g/ml,
a buoyant density characteristic of IMV (Fig. 2A). MVA
particles, on the other hand, were found in both intracel-
lular and extracellular fractions (Figs. 2B and 2D). The
cell-associated MVA was composed of IMV (26%) and to
an even larger extent enveloped virus (63%) displaying a
lighter buoyant density (1.23 g/ml). Whereas very little
extracellular virus (2%) was detectable in the CsCl gra-
dients after infection with the COP strain (Fig. 2C), MVA
infection led to the accumulation of a larger amount of
extracellular virus (11%) with a buoyant density charac-
teristic of EEV (Fig. 2D). Analysis of the ability of the
original Ankara strain to give rise to the various virus
forms showed that it behaved like the COP strain with
respect to the formation of both intra- and extracellular
enveloped virus (results not shown).
MVA particles are not labeled with antibody against a
surface IMV protein but are labeled with antibody against
d MVA were observed under the electron microscope after negative
ifferent enlargements of MVA particles. A bar length marker is providedan EEV protein. The surface of IMV is covered by a
14-kDa protein encoded by the A27L ORF (10). In an
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surface, purified viral particles from both strains were
incubated with antibodies against the A27L protein fol-
lowed by an anti-species antibody coupled with colloidal
gold and silver enhancement. Under these conditions,
the COP surface was heavily labeled (Fig. 3A) whereas
the MVA surface was mostly unlabeled (Fig. 3B). Where
envelope damage was apparent, the MVA surface was
labeled (arrows in Fig. 3B) suggesting the presence of an
underlying A27L protein. Furthermore, extensive ultra-
sonic treatment enhanced the degree of labeling with the
A27L antibody indicating that this procedure damaged
the envelope (not shown). To confirm that the origin of
the envelope surrounding MVA particles is the viral en-
velope found on the IEVs and EEVs we incubated puri-
fied viral particles with antibodies against EEV proteins
encoded either by the B5R (11, 12) or the F13L ORFs (13).
A relatively strong background labeling was apparent
with the anti-B5R serum in both virus samples (Figs. 3C
and 3D) which could be due either to some free B5R
proteins in the virus stocks or to unrelated antibodies
FIG. 2. CsCl gradient analysis of COP and MVA produced in CEF.
CEF were infected with COP (A, C) or MVA (B, D) at 0.1 PFU per cell for
30 h in the presence of [3H]thymidine. Cell-associated (A, B) or extra-
ellular virus (C,D) was then recovered and centrifuged on CsCl gra-
ients. The refractive indexes and TCA precipitable radioactivity of
ach fraction were then determined. Triangles, buoyant density;
quares, CPM [3H]thymidine. Note the differences in the CPM scales of
each graph. The relative amount of each virus form is indicated at the
bottom. The amount of radioactivity in each peak was calculated with
respect to the amount in all three peaks. The following fractions were
summed for each virus form: IMV, fractions 5 to 9; IEV 1 CEV, fractions
11 to 16; EEV, fractions 12 to 18.present in the rabbit serum. Despite this background it
could be clearly noticed that the antibody against theB5R protein strongly labeled MVA (Fig. 3D) but did not
significantly label the COP particles (Figs. 3C). This sug-
gested that the MVA envelope mainly corresponds to the
single envelope that surrounds CEV and EEV and not to
the double envelope that surrounds IEV since the bulk of
the B5R protein in the latter lies between the two enve-
lopes of the IEV (11, 14) and would not be readily reached
by an antibody without prior permeabilization. In agree-
ment with this result, antibody against the F13L protein,
which is exposed on the outside surface of IEV and on
the inside of EEV (14, 15), failed to label the COP strain
(Fig. 3E) and the MVA strain (Fig. 3F) but strongly labeled
the MVA envelope when it was damaged (Fig. 3G).
MVA is not efficiently neutralized by antibodies against
the COP strain. We wondered whether the distinct sur-
face properties of MVA may affect its ability to be neu-
tralized by anti-VV sera. To investigate this, mice were
inoculated twice intramuscularly with COP and the sera
obtained were tested in a neutralization assay with COP
and MVA. As illustrated in Fig. 4, COP was efficiently
neutralized by sera taken from the animals over a 60-day
period whereas MVA largely resisted neutralization. Fur-
thermore, as expected from the immunolabeling experi-
ment in Fig. 3, MVA was also more resistant to neutral-
ization by an anti-A27L antibody than the COP strain
(results not shown).
Discussion. These studies have demonstrated that
most of the virus produced during a productive MVA
infection is enveloped whether the virus is amplified on
CEF or BHK21 cells (not shown). Quantification by CsCl
gradient analysis indicated that as much as 74% of MVA
was enveloped in contrast to only 22% for the COP strain.
The relative proportion of double-enveloped and single-
enveloped, cell-associated virus was not precisely de-
termined although the latter appeared to predominate in
the purified MVA stocks examined by electron micros-
copy. It is likely that during purification the outer enve-
lope of the IEVs may be removed to some extent to
generate EEV-like particles. Work on other VV strains,
such as IHD-J which produces a large amount of EEV,
has shown that the enveloped form of VV is very fragile
(16). Although some 22% of COP particles were appar-
ently enveloped according to CsCl gradient analysis,
enveloped virus was rarely detected after standard puri-
fication of the virus. Thus it is particularly surprising that
much of the virus produced after purification of MVA
remained enveloped despite the harsh treatment asso-
ciated with the procedure. This suggests that the enve-
lope surrounding MVA may be particularly resistant due
to a tighter association with the IMV.
Sequencing of the MVA genome (5) has shown that all
of the known genes encoding VV envelope proteins are
intact, with the exception of the A36R ORF (MVA 147R)
which has two small internal deletions. Thus it is possi-
ble that alterations of this protein in the MVA strain may
. The a
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and stability. However, a number of other genes encod-
ing proteins of unknown function are deleted or altered
in MVA and any one of these or combinations of muta-
tions may be responsible for the particular phenotype of
MVA with respect to EEV formation. In any case, during
the course of cell culture passaging the original Ankara
strain acquired mutations leading to the enveloped phe-
notype of MVA since Ankara behaved more like the COP
strain. One notable feature associated with MVA infec-
tion of permissive cells is the reduced cytopathic effect
(CPE) compared to the parental Ankara strain (2) as well
as the COP strain used in this work. A reduced CPE
could account for better preservation of a functional
FIG. 3. Immunolabeling of MVA and COP. COP and MVA particles we
protein (C and D), or the F13L protein (E, F, and G). COP: A, C, E. MVA
that is damaged and labeled with antibodies against the A27L protein
particle (arrowhead) .A bar length marker is provided in the bottom rigGolgi apparatus required for the generation of IEV and
EEV (17). Interestingly, Carroll and Moss (2) also noticedextensive membrane wrapping of immature particles in
MVA-infected HeLa cells but found no difference at the
ultrastructural level between MVA and its parental An-
kara strain in permissive CEF or BHK-21 cells. However,
the fact that different laboratories are working with
slightly different MVA isolates following cell passaging or
cloning cannot be excluded. In this regard it is interest-
ing to note that a recombinant MVA virus obtained from
Gerd Sutter in Munich, amplified and purified by us, also
contained a majority of enveloped virus.
The production of large amounts of enveloped virus by
MVA has a number of consequences. First, as shown in
this study, MVA infectivity is poorly neutralized by anti-
bodies against the COP strain and against the A27L
nolabeled with antibodies against the A27L protein (A and B), the B5R
F, and G. The arrows in B point toward a region of the MVA envelope
rrows in G point toward an envelope that has detached from an MVA
d corner of each panel.re immu
: B, D,protein. The fact that Czerny et al. (18) were able to
neutralize virus infectivity and immunolabel MVA with
13RAPID COMMUNICATIONantibodies against the A27L protein is probably related
to their use of virus prepared by precipitation with Frigen
113 (trichlorotrifluoroethane) as well as extensive soni-
cation, procedures which both damage the envelope
(16). Our finding that MVA resisted neutralization by
mouse antibodies against the COP strain is in agreement
with previous data showing that enveloped virus is re-
sistant not only to neutralization by antibodies against
IMV particles but also to neutralization by antibodies
against envelope proteins (16). The ability of MVA to
resist neutralization by anti-VV antibodies may enable it
to partially overcome the humoral immunity that is com-
mon in people who were previously vaccinated against
smallpox or even vaccinated with other VV recombinants.
The presence of an envelope around MVA may also
account for the ability of MVA recombinants encoding
foreign antigens to be particularly effective in immuniza-
tion protocols. The envelope enables VV to bind to dis-
tinct cell receptors (19) and may allow for a more efficient
in vivo infection since it is this form of the virus that is
considered to be the natural means of viral propagation.
Finally, the fact that enveloped MVA appears to be rela-
tively stable, even after purification, suggests that this
virus is more appropriate than other VV strains for the
construction of recombinant viruses containing chimeric
envelopes in view of targeting infection or raising im-
mune responses against antigens expressed on the EEV
surface.
Materials and Methods. Cells and virus. Primary chick
embryo fibroblasts (CEF) were established from 11-day-
old embryos and grown in Eagle’s basal medium sup-
plemented with tryptose phosphate broth and 10% fetal
FIG. 4. Neutralization of COP and MVA. Mice were infected by two
intramuscular injections of COP. The sera were collected either prior to
the first inoculation (Day 0) or at the indicated days after the second
inoculation. The sera were diluted 1/20 and used in a neutralization
assay with MVA or COP. The results are plotted as the percentage of
PFU surviving incubation with the sera. Triangles, COP; squares, MVA.calf serum. BHK21 cells were grown in BHK21 medium
(Glasgow MEM) supplemented with tryptose phosphatebroth and 10% fetal calf serum. A lyophilized vaccine
preparation of MVA (II/85) was obtained from Anton Mayr
and diluted in 1 ml of PBS. The virus was plaque purified
twice on CEF and plaques were screened by PCR for
deletion II (primer 1 OTG7475: ctctctagcaaagatgcatttaag-
gcggatgtc; primer 2 OTG7476: tggccattatactagaactatag-
gtgcgttgta) and deletion III (primer 1 OTG7473: ggttgttgat-
ggatctgtgatgcatgcgatagctga and primer 2 OTG7474: gaat-
gcacatacataagtaccggcatctctagcgat). One viral clone
designated MVATGN33.1. was chosen for further studies
and is referred to hereafter as MVA. A clonal isolate of
the VV Copenhagen strain was also used whereas the
vaccinia virus Ankara strain (CVA) obtained from Gerd
Sutter was employed without prior plaque purification.
Titration of virus was performed on CEF under low melt-
ing temperature agarose and plaques were stained us-
ing neutral red. Virus was purified from infected CEF or
BHK21 cells by the standard sucrose gradient procedure.
No difference in the rate of migration on sucrose gradi-
ents was observed between the MVA and COP strains
although the virus band in the former was slightly
broader.
Electron microscopy and immunolabeling. For nega-
tive staining of purified virus, formwar carbon-coated
nickel grids were made hydrophilic by submitting them to
a glow discharge. Virus was deposited on the grids for 1
min and the grids were stained for 20 s with 2% uranyl
acetate or 2% phosphotungstic acid. For immunolabeling
of virus, grids prepared as above were first preincubated
with blocking buffer (PBS containing 5% BSA, 0.1% cold
water fish skin gelatin, 1% normal goat serum) for 30 min.
About 107 PFU of purified virus (10 ml) was then depos-
ited on the grids for a minimum of 2 h. The grids were
washed several times with PBS containing 0.1% acety-
lated BSA (PBS–BSAc, Aurion, The Netherlands) and
antibodies were added at a 1/100 dilution. After 2 to 3 h
of incubation the grids were washed twice for 5 min in
PBS–BSAc and then goat anti-rabbit Fab or goat anti-
mouse Fab, both coupled to ultrasmall colloidal gold
particles (Aurion) and used at a 1/40 dilution, was added
for 2 h. The grids were again washed twice with PBS–
BSAc, twice with PBS, and fixed for 10 min with 2.5%
glutaraldehyde in PBS. The grids were washed five times
with distilled water and the ultrasmall gold particles
enhanced with silver for 30 min using the SE-EM kit from
Aurion. Finally, the grids were washed with water to stop
enhancement and negative staining was performed with
2% uranyl acetate in water and the grids were left to dry.
Electron microscopic observations were carried out us-
ing a Philips CM120 Biotwin electron microscope at 120
kV. Electron micrographs of gold-labeled particles were
underexposed to facilitate visualization of the silver-en-
hanced gold particles.Antibodies and neutralization assays. To prepare anti-
bodies against the A27L protein the corresponding cod-
[14 RAPID COMMUNICATIONing region was amplified from MVA genomic DNA by
PCR using the primers OTG 12707 (59-ggggggatccatg-
gacggaactcttttcccc-39) and OTG12708 (59-ggggggaattct-
tactcatatggacgccgt-39). The gene fragment was then in-
serted into the BamHI and EcoRI sites of the pGEX2T
vector (Pharmacia, Uppsala, Sweeden) to generate a
plasmid designated pTG14367. Expression of the fusion
gene GST-A27L was performed in the BL21 strain of
Escherichia coli at 20°C for 4 h in the presence of 1 mM
IPTG in order to obtain a soluble fusion protein. Purifi-
cation of native A27L from the GST-fusion was performed
after thrombin cleavage according the procedure de-
scribed by Pharmacia. Mice were immunized intraperi-
toneally (IP) with 10 mg of A27L in complete Freund’s
adjuvant and boosted 14 days later with 10 mg of A27L
injected IP in incomplete Freund’s adjuvant. Sera were
collected 10 days after the boost and pooled. To prepare
sera against the VV Copenhagen strain, 8-week-old
C57Bl6 mice (Charles River, Rouen, France) were vacci-
nated with 107 PFU of VV containing predominantly IMV
particles. Animals were inoculated twice by the intra-
muscular route and sera were obtained at days 10, 31, 46,
and 60 after the boost. Sera from several mice for each
time point after virus inoculation were pooled and tested
for neutralizing antibodies.
For neutralization assays, 107 PFU of crude virus prep-
arations was diluted in 1 ml PBS containing cations and
1% fetal calf serum. Mouse serum was added at a 1/20
dilution and incubation was performed for 4 h at room
temperature. Virus was then titrated on CEF monolayers
under low melting agarose and plaques were stained
with neutral red.
Density gradient analysis. The buoyant densities of
extracellular virus and intracellular virus were deter-
mined as described previously (20). Briefly, CEF (about
20 3 10E6 cells) were infected with 0.1 PFU per cell.
3H]Thymidine (10m Ci/ml) was added after the first hour
and left for 30 h until the end of the infection. At this point
the culture medium was removed and centrifuged at
4500 rpm for 10 min and the extracellular virus in the
supernatant was recovered. Infected cells were removed
from the plates by scraping, resuspended in 10 mM
Tris–HCl buffer (pH 8.8) for 10 min, and lysed by dounce
homogenization. The nuclei were pelleted by centrifuga-
tion at 1500 rpm for 5 min and the supernatants further
cleared by centrifugation for 10 min at 4500 rpm. The
cell-associated virus in these supernatants as well as
the extracellular virus was concentrated by pelleting
through a 36% sucrose cushion in a SW 28 Beckman
rotor for 2 h at 12000 rpm. The pellets were then resus-
pended in 1 ml and overlaid onto discontinuous CsCl
gradients (2.5 ml at 1.3 g/ml, 3.5 ml at 1.25 g/ml, 4.5 ml at
1.2 g/ml). The gradients were spun for 95 min at 2500 rpm
and 20°C in a Beckman SW41 rotor. Gradient fractions
were then collected from the bottom of the tubes andrefractive indexes were determined. The samples were
then precipitated with 5% trichloroacetic acid, the precip-
itates were recovered onto glass fiber filters (Whatman
GF/A), and the radioactivity was counted.
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